Maternal Mental Health Market To Reach $45.72 Billion By 2030 | Therapy Mama, Canopie, Pfizer, Inc., Viatris, Inc.

The global maternal mental health market size is expected to reach USD 45.72 billion by 2030, growing at a CAGR of 28.43%, according to a new report by Grand View Research, Inc. Maternal mental health issues are a global concern that affects women of various countries and cultures. It refers to the emotional well-being of women during the pregnancy and postpartum period. The market is driven by the increasing incidence of post-partum depression, increasing awareness programs, and efforts in improving practices around maternal mental healthcare among other factors.

Request a free sample PDF copy: https://www.grandviewresearch.com/industry-analysis/maternal-mental-health-market-report/request/rs1?utm_campaign=tushar-d

Efforts are being undertaken to increase awareness of maternal mental health issues and improve access to treatment and support. These efforts include screening for issues during pregnancy and after childbirth, training healthcare providers to recognize and treat these conditions, and government funding & providing resources to women and their families. For instance, in May 2023, in Canada, the Associate Minister of Health and the Minister of Mental Health and Addictions announced funding for three organizations totaling over USD 857,000 for their initiatives promoting the treatment of maternal mental health conditions. The Women's College Hospital will receive USD 372,000 from Health Canada to help create national physician guidelines for perinatal mood disorders.

In addition, the Public Health Agency of Canada will provide USD 279,000 to the Canadian Mothercraft Society to encourage secure attachment of mothers with their kids and USD 206,000 to the Families Matter Society of Calgary to lead projects aimed at promoting positive mental health conditions by enhancing their access to support services for black parents who are dealing with perinatal mood disorders.

Patients who gave birth to a child during the coronavirus (COVID-19) pandemic reported experiencing more stress during labor. In addition, depression symptoms were present in 29.6% of pregnant patients evaluated during the pandemic. COVID-19 has consequently significantly impacted peripartum mental well-being outcomes. However, the lack of access to diagnosis and pharmacological or psychological treatment during the pandemic has impacted the market.

On the other hand, the workforce shortage is expected to hinder the growth of this market. For example, one-third of Americans-about 37%-live in locations with a shortage of mental health professionals. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), there will be a shortage of 31,000 full-time equivalent mental health professionals in the U.S. by 2025. This shortage is attributed to a lack of resources, comparatively poor salaries, an aging workforce, a low number of people joining the field, and a concentration of providers in wealthy urban and suburban areas.

Maternal Mental Health Market Report Highlights

• The pregnancy and postpartum general anxiety segment accounted for the largest share in 2022. Increasing awareness and recognition of perinatal mental health issues, including anxiety disorders is the major factor driving the segment growth
• The postpartum depression segment is expected to witness a lucrative CAGR through 2023-2030 owing to the favorable reimbursement scenario, increasing awareness for screening, and approval of novel therapies
• Interpersonal psychotherapy (IPT) dominated the market in 2022 as it is considered an effective therapy for treating a variety of these conditions
• The North American market encompasses the

U.S. and Canada. The factors contributing to the market growth in the region include robust government funding, increasing research, and the presence of prominent players in this region
Maternal Mental Health Market Segmentation
Grand View Research has segmented the global maternal mental health market based on disease indication, therapy, and region:

Maternal Mental Health Disease Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Postpartum Depression
• Dysthymia
• Pregnancy and Postpartum General Anxiety
• Pregnancy and Postpartum OCD
• Birth-Related PTSD
• Others

Maternal Mental Health Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Antidepressants
o Selective serotonin reuptake inhibitors (SSRIs)
o Tricyclic antidepressants (TCAs)
o Others
• Interpersonal Psychotherapy (IPT)
• Cognitive Behavioral Therapy (CBT)
• Others

Regional Insights

North America accounted for the largest revenue share of 41.93% in 2022 and is expected to grow at the fastest CAGR during the study period. Favorable reimbursement scenarios, increasing incidence of PPD, growing awareness programs, and robust healthcare infrastructure are the major factors driving the growth of the region. As per the data published by Postpartum Depression, the reported rate of some clinical PPD among new mothers is 10% to 20%. A recent study indicated that one in seven women may develop PPD in the year following childbirth. With over four million live births being reported annually in the U.S., this corresponds to approximately 600,000 PPD diagnoses. In the U.S., approximately 900,000 women who had miscarried or had a stillbirth suffered from PPD annually.

In addition, Texas lawmakers enacted a bill in 2021 that extended Medicaid coverage for six months following childbirth, compared to the current 2-month limit. In the 2023 session, other bills that call for a 1-year extension have also been introduced. Additional health-related legislation priorities for the 2023 session include expanding access to and coverage for contraception, providing gender-affirming treatment for trans adolescents, and providing mental health services for youth throughout Texas. Implementation of such legislation will offer lucrative opportunities during the review period.

List of Key Players in the Maternal Mental Health Market
• Therapy Mama
• Canopie
• Pfizer, Inc.
• Viatris, Inc.
• GlaxoSmithKline, Inc.
• Alembic Pharmaceuticals Limited
• Mallinckrodt, Inc.
• Sage Therapeutics, Inc.
• Bausch Health Companies, Inc.
• Magellan Health, Inc.
• Others

Free Access For Authoritative Research: https://www.grandviewresearch.com/industry-analysis/maternal-mental-health-market-report?utm_campaign=tushar-d

Contact Us:
Grand View Research, Inc.
201 Spear Street 1100,
San Francisco, CA 94105
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Grand View Research is an India & U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

This release was published on openPR.